Summary Blocking PD-1/PD-L1 signaling transforms cancer therapy and is assumed to
unleash exhausted tumor-reactive CD8+ T cells in the tumor microenvironment (TME) …

Lymph node (LN)–resident lymphatic endothelial cells (LEC) mediate peripheral tolerance
by self-antigen presentation on MHC-I and constitutive expression of T-cell inhibitory …

Tumor responses to programmed cell death protein 1 (PD-1) blockade therapy are mediated
by T cells, which we characterized in 102 tumor biopsies obtained from 53 patients treated …

Tissue-resident memory CD8+ T (Trm) cells mediate potent local innate and adaptive
immune responses and play a central role against solid tumors. However, whether Trm cells …

Anti–PD-1/PD-L1 therapy, either by anti–PD-1 antibody or anti–PD-L1 antibody, has efficacy
by reinvigorating tumor-infiltrating CD8+ T cells in a subset of patients with cancer, but it has …

Summary PD-1/PD-L1-checkpoint blockade therapy is generally thought to relieve tumor cell-
mediated suppression in the tumor microenvironment but PD-L1 is also expressed on non …

PD-1 blockade exerts clinical efficacy against various types of cancer by reinvigorating T
cells that directly attack tumor cells (tumor-specific T cells) in the tumor microenvironment …

Central memory CD8+ T cells (TCM) and effector memory CD8+ T cells (TEM) are found in
humans and mice; however, their relative contributions to host immunity have only recently …

Tumor relapses remain a serious problem after allogeneic stem cell transplantation
(alloSCT), despite the long-term persistence of minor histocompatibility antigen (MiHA) …

A novel population of memory CD8+ T cells called resident memory T cells (TRM) has been
identified based on their phenotype (CD103, CD69) and on their local tissue residency …